Literature DB >> 28807489

A model to estimate survival in ambulatory patients with hepatocellular carcinoma: Can it predict the natural course of hepatocellular carcinoma?

Won-Mook Choi1, Su Jong Yu2, Hongkeun Ahn3, Hyeki Cho3, Young Youn Cho3, Minjong Lee4, Jeong-Ju Yoo5, Yuri Cho6, Dong Hyeon Lee7, Eun Ju Cho3, Jeong-Hoon Lee3, Yoon Jun Kim3, Jung-Hwan Yoon3.   

Abstract

BACKGROUND: Several hepatocellular carcinoma (HCC) staging systems are available including the newly developed staging system, the Model to Estimate Survival in Ambulatory HCC patients (MESIAH); however, whether these staging systems could predict the natural course of HCC is largely unknown.
METHODS: 1013 patients with history of HCC treatment and 111 patients without any history of treatment till death or last follow-up at a single tertiary hospital were included.
RESULTS: The MESIAH score showed a better discrimination ability, with a C-statistic of 0.835 [95% confidence interval (CI), 0.810-0.861] in the group of treated patients compared to the Barcelona Clinic Liver Cancer (BCLC) staging system [0.739 (95% CI, 0.709-0.769)] before propensity score matching. However, the MESIAH score failed to stratify patients according to their risk of death in the group of untreated patients unlike the BCLC staging system. Propensity score matching analysis confirmed that the MESIAH score was most strongly influenced by whether treatment was given or not.
CONCLUSIONS: Although the MESIAH score provided better prognostic stratification than other staging systems in treated HCC patients, it was not helpful in predicting the natural course of HCC. Since the treatment affects patient outcome and prognosis, it is necessary to develop a new staging system that can also reflect the natural course of HCC.
Copyright © 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma; Natural history; Overall survival; The model to estimate survival in ambulatory hepatocellular carcinoma patients (MESIAH)

Mesh:

Year:  2017        PMID: 28807489     DOI: 10.1016/j.dld.2017.07.007

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  4 in total

1.  Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal.

Authors:  Li Li; Xiaomi Li; Wendong Li; Jinglong Chen; Wei Li; Xiaoyan Ding; Yongchao Zhang
Journal:  BMC Cancer       Date:  2022-07-09       Impact factor: 4.638

2.  Predictive scores for hepatocellular carcinoma: a race with no winners?

Authors:  Raffaella Tortora; Marco Guarracino; Giovan Giuseppe Di Costanzo
Journal:  Ann Transl Med       Date:  2020-10

3.  Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature.

Authors:  Michele Campigotto; Mauro Giuffrè; Anna Colombo; Alessia Visintin; Alessandro Aversano; Martina Budel; Flora Masutti; Cristiana Abazia; Lory Saveria Crocé
Journal:  World J Hepatol       Date:  2020-12-27

4.  Central hepatectomy for hepatocellular carcinoma in a patient with anti-Gerbich antibody.

Authors:  Teruo Komokata; Maki Inoue; Bibek Aryal; Hiroto Yasumura; Chinami Mori; Mituharu Nomoto; Mamoru Kaieda; Shuichi Hanada
Journal:  Surg Case Rep       Date:  2020-06-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.